CooperSurgical Expands Fertility, Labor & Delivery With $1.6B Acquisition Deal

by Vandana Singh, Benzinga Editor

November 11, 2021 9:01 AM | 1 min read |

CooperCompanies COO has agreed to acquire Generate Life Sciences for $1.6 billion.
Privately held Generate Life Sciences provides donor egg & sperm for fertility treatments, fertility cryopreservation services, and newborn stem cell storage (cord blood & cord tissue).
“This acquisition is a strong strategic fit for CooperSurgical,” said Al White, Cooper’s President, and CEO.
The transaction is anticipated to close in Cooper’s Q1 of FY22.
Generate Life Sciences reported approximately $250 million in trailing twelve-month revenues as of September 30, 2021.
The acquisition is expected to be accretive to Cooper’s non-GAAP EPS by approximately $0.30 in the first year after closing.
See the related presentation here.
Price Action: COO shares are down 2.10% at $425 during the premarket session on the last check Thursday.

Posted In: M&A News Health Care Movers Trading Ideas General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.